Biomanufacturing

Global Biomanufacturing Market to Reach US$31.5 Billion by 2030

The global market for Biomanufacturing estimated at US$21.5 Billion in the year 2024, is expected to reach US$31.5 Billion by 2030, growing at a CAGR of 6.6% over the analysis period 2024-2030. Continuous Upstream Biomanufacturing, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$19.0 Billion by the end of the analysis period. Growth in the Single-Use Upstream Biomanufacturing segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.9 Billion While China is Forecast to Grow at 10.6% CAGR

The Biomanufacturing market in the U.S. is estimated at US$5.9 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$6.6 Billion by the year 2030 trailing a CAGR of 10.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Biomanufacturing Market – Key Trends & Drivers Summarized

Why Is Biomanufacturing Reshaping the Global Landscape of Pharmaceutical and Industrial Production?

Biomanufacturing is revolutionizing modern production processes by using living organisms, cells, or biological systems to develop a broad spectrum of products including pharmaceuticals, biofuels, industrial enzymes, food ingredients, and biomaterials. Unlike traditional chemical manufacturing that often relies on high temperatures, toxic solvents, and fossil-derived inputs, biomanufacturing leverages biologically-based and often renewable methods to produce complex molecules with high specificity and efficiency. In the pharmaceutical sector, biomanufacturing plays a central role in the production of biologics, including monoclonal antibodies, vaccines, hormones like insulin, and gene or cell therapies. These therapies often require precise protein structures and post-translational modifications that only living cells can provide. The value of biomanufacturing extends beyond healthcare—it is also transforming the agricultural, energy, and textile sectors through sustainable alternatives like microbial fermentation for fertilizers, algae-based biofuels, and biodegradable biopolymers. As global industries aim to lower carbon footprints and reduce environmental impact, biomanufacturing offers a cleaner, safer, and more sustainable alternative that aligns with ESG goals and circular economy models. Its ability to produce high-value, low-volume products with minimal waste and energy consumption is especially relevant in an era of increasing resource scarcity and climate consciousness. Biomanufacturing isn’t just an upgrade to traditional production—it represents a fundamental shift in how we conceptualize, design, and scale the manufacturing of the future.

How Are Technological Advancements Powering the Next Generation of Biomanufacturing?

Technological innovations are significantly expanding the potential, precision, and productivity of biomanufacturing processes. Central to this advancement is synthetic biology, which enables scientists to engineer microorganisms like yeast, bacteria, or mammalian cells with custom-designed genetic blueprints that optimize metabolic pathways for higher yield and target specificity. CRISPR and other gene-editing tools allow for rapid, precise modifications that were previously labor-intensive and unpredictable. Meanwhile, advances in bioprocessing technologies such as single-use bioreactors, continuous manufacturing, and perfusion systems are increasing scalability and reducing production costs. Digitalization is also transforming biomanufacturing—smart factories equipped with real-time sensors, data analytics, and AI algorithms enable predictive maintenance, process optimization, and quality assurance at unprecedented levels. Automation through robotics and digital twins allows for high-throughput experimentation and accelerated product development cycles. Innovations in cell culture media, feed strategies, and upstream/downstream integration have improved process yields and consistency across batches. Furthermore, machine learning is being used to simulate fermentation outcomes, optimize protein folding, and reduce time to market. Cloud-based platforms now support collaborative development, enabling stakeholders from academia, biotech startups, and big pharma to share data and refine processes in real time. These technologies collectively push biomanufacturing beyond laboratory confines into scalable, efficient, and industrial-grade operations that can adapt to evolving demand and therapeutic complexity. As innovation continues to converge across biology, computing, and engineering, biomanufacturing is positioned to deliver faster, cheaper, and more customizable production solutions on a global scale.

Which Sectors and Global Markets Are Leading the Adoption and Expansion of Biomanufacturing?

The adoption of biomanufacturing is accelerating across a diverse array of industries and global regions, each leveraging its capabilities to address specific economic, healthcare, and environmental needs. In the pharmaceutical and biotechnology sectors, leading companies in the United States and Europe are heavily investing in biomanufacturing to meet the growing demand for biologics and personalized medicine. With blockbuster biologics accounting for a significant portion of pharmaceutical revenues, companies like Genentech, Amgen, and Roche are expanding their biomanufacturing footprints both in-house and through contract development and manufacturing organizations (CDMOs). In Asia-Pacific, countries like China, India, South Korea, and Singapore are rapidly scaling up biomanufacturing capabilities, supported by government incentives, skilled labor, and expanding healthcare markets. China, for instance, is making biomanufacturing a strategic priority under its "Made in China 2025" initiative. The food and agriculture sectors are adopting biomanufacturing to produce alternative proteins, enzymes, and bio-based preservatives, catering to a growing global demand for plant-based and sustainable diets. Environmental and energy sectors are leveraging microbial and algae-based systems to generate biofuels and biodegradable plastics, especially in regions where green technology investment is high. Latin America is beginning to emerge as a key player in agricultural biomanufacturing, thanks to its vast biomass availability and biodiversity. In all these regions, biomanufacturing is being integrated into broader national strategies focused on bioeconomy development, innovation ecosystems, and industrial decarbonization. This multi-sectoral and global push is transforming biomanufacturing into a foundational industry with far-reaching economic and environmental impact.

What Is Fueling the Growth in the Global Biomanufacturing Market?

The growth in the global biomanufacturing market is driven by several interconnected factors related to healthcare demand, environmental urgency, technological maturity, and supportive policy frameworks. One of the most prominent drivers is the exponential rise in demand for biologics, including complex therapeutics like monoclonal antibodies, gene therapies, and mRNA vaccines. This demand is further amplified by the global aging population and the increasing incidence of chronic diseases that require long-term, biologically-targeted treatment solutions. The COVID-19 pandemic demonstrated the strategic importance of resilient and scalable biomanufacturing capacity, leading to massive investments in both public and private infrastructure. Environmental sustainability goals are also driving adoption, as industries seek alternatives to petrochemical-based manufacturing. Biomanufacturing offers a low-emission, waste-minimizing pathway that aligns with net-zero targets and circular economy models. On the regulatory front, faster approval pathways for biologics and biosimilars, along with government grants and tax incentives, are lowering barriers to entry for startups and accelerating innovation. Advances in automation, process control, and modular facility design are reducing time-to-market and enabling flexible production capable of meeting both large-scale and niche demands. Additionally, increasing collaboration between academia, biotech companies, and multinational manufacturers is creating innovation clusters and accelerating the development of next-generation platforms. As more industries and governments recognize the strategic value of biological manufacturing, investment and innovation in this field are set to continue rising. The result is a dynamic, expanding market with the potential to redefine global production norms—where biology becomes the engine of industry.

SCOPE OF STUDY:

The report analyzes the Biomanufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Workflow (Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing, Downstream Biomanufacturing); End-Use (BioPharmaceuticals Companies End-Use, Research Institutions End-Use, CMOs / CDMOs End-Use); Application (Monoclonal Antibodies Application, Hormones Application, Vaccines Application, Recombinant Proteins Application, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• AbbVie Inc.
• Amgen Inc.
• Biocon Limited
• BioNTech SE
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Catalent, Inc.
• Cytiva
• Eli Lilly and Company
• FUJIFILM Diosynth Biotechnologies
• Genentech, Inc.
• Ginkgo Bioworks Holdings, Inc.
• Lonza Group AG
• Moderna, Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Roche Holding AG
• Samsung Biologics Co., Ltd.
• WuXi Biologics

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.